Compare Merck & Co., Inc. (MRK) vs Opendoor Technologies Inc (OPEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Opendoor Technologies Inc — how do they compare? Merck & Co., Inc. trades at $148.1 (market cap $366.28B), while Opendoor Technologies Inc trades at $3.02 (market cap $2.96B). The key difference: Merck & Co., Inc. is far larger — about 123.7× Opendoor Technologies Inc's market cap, and Merck & Co., Inc. pays a 2.29% dividend while Opendoor Technologies Inc pays none. Which is the better fit depends on your goals.
| MRK | OPEN | |
|---|---|---|
Market Cap | $366.28B | $2.96B |
Sector | Health | Real Estate |
52-Week High | $156.43 | $10.52 |
52-Week Low | $77.60 | $3.00 |
Enterprise Value | $413.04B | $4.03B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
Opendoor Technologies (OPEN) trades at $3.07, down 2.54% on the day, near its 52-week low. The stock exhibits a bearish technical trend with negative moving averages, while fundamentals show declining revenue to $4.37 billion in 2025 and a net loss of $1.30 billion. Recent news highlights the launch of Opendoor Home Loans and a $158 million share buyback, but the company faces persistent profitability challenges amid a weak housing market.
The outlook remains cautious with high execution risks and negative margins, though analyst consensus suggests a moderate buy rating with a $3.58 price target. Key risks include housing market sensitivity and capital intensity, but cost-cutting and volume growth offer potential upside if the turnaround gains traction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Opendoor Technologies Inc
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →
